M E D I C A
WALES
S P E C I A L
medica special
2 0 0 7
Medica 14-17 November 2007 - Messe Dusseldorf, Germany
3
The Welsh Pavilion: Hall 16 Stand 39 This MediWales Review ‘Medica Special’ is your introduction to the thriving medical technology sector in Wales. It includes a directory of all of those companies involved in the IBW trade mission and pavilion at Medica 2007 as well as a snapshot of some of the most exciting products and services being offered by Welsh companies in this sector.
Medica is the world’s largest medical trade fair and runs alongside the leading international fair for medical manufacturing supplies, ComPaMED. MEDICA and ComPaMED together will occupy all 18 halls of the Düsseldorf Exhibition Centre and organisers expect over 4,300 exhibitors. MEDICA covers the entire range of outpatient and in-patient health care, including: electrical medicine/medical devices ● laboratory technology/ diagnostics ● physiotherapy/ orthopaedic technology ● medical supplies (essential supplies and consumables) ● information and communication technology ● textiles ● medical furniture ● furnishings ● facility management ● building services. At the same time, ComPaMED addresses all aspects of supplies to the medical manufacturing sector: raw materials ● components ● parts ● packaging ● services for use in medical device production.
International Business Wales (IBW) is the Welsh Assembly Government’s international trade and investment arm, forming part of the Department of Innovation, Enterprise and Networks. It acts as the driving force in establishing alliances
between companies in Wales and their counterparts overseas. At the same time it actively seeks out inward investment opportunities for client companies looking to Europe and the UK as a preferred international business location.
Contents Medical Technology Wales Pavilion Directory
The Welsh Assembly Government is a democratically elected body, which was established in May 1999. It has devolved powers and responsibilities for developing and implementing policies in Wales on a broad range of issues, including economic development, education, the environment, agriculture, housing, roads and transport. The Welsh Assembly works closely with the UK Parliament in developing primary legislation and has powers to introduce secondary legislation of its own.
4 10-17
BB International
18
Haemair
19
JMJ
20
Molecular Light Technology
23
PDR
24
Wound Healing Research Unit
25
Zarlink
26
MediWales has been active for over sixteen years and is the representative body for the medical sector in Wales. Supported by the Welsh Assembly Government, MediWales is owned by its members and led by directors drawn from senior industrialists and academics in Wales. MediWales generates a unique environment for networking, collaboration and communication between industry, higher education and heath service members. This is delivered through an active schedule of seminar events and publications, supported by the MediWales website and maintained via constant communication with members and stakeholders. From this pivotal role, MediWales is able to represent both its members and the wider sector to governmental and international partners.
M E M B E R
5 Schooner Way, Atlantic Wharf, Cardiff CF10 4DZ
MediWales is a founder member of Medilink UK, the network of regional medical technology organisations that represents the interests of around 3000 organisations across the UK.
T/F:
029 2047 3456
Email:
debbie.laubach@mediwales.com coralie.palmer@mediwales.com gwyn.tudor@mediwales.com
Web:
www.mediwales.com
M e d i c a
S p e c i a l
2 0 0 7
WELSH MEDICAL TECHNOLOGY
4
5
Welsh medical technology reaches out The growth of Welsh medical technology is galvanising every stage of the product development route, across the full technological spectrum from commodities to highly complex devices. This is a growth not only of capacity but of sophistication, both in technological innovation and its effective management. Wales has long punched above its weight in terms of its capacity for innovation. Now Welsh companies and academic institutions are also increasingly engaging at a high level with financial institutions, whether indigenous to Wales or from further afield. They’re therefore better at raising the capital required to finance the cash-hungry and longterm nature of R&D in healthcare, through large-scale and often private sources. This capability is matched with expertise in the systemic management of the innovation process. Even with simpler new products, getting them to market requires groups or individuals to combine forces with others outside their familiar territory. The more complex an innovative technology, the more collaboration becomes integral to the process of its development. Managing that collaborative process is increasingly recognised as a vital capability, and Welsh organisations are already demonstrating a high level of competence.
Meanwhile the economic environment is one that is now properly equipped to provide for the sector’s distinctive needs, particularly in relation to the high regulatory barriers and long timescales characteristic of complex innovative technologies. Companies can source within Wales the full range of essential services, from clinical trials to product design to intellectual property expertise. In sum, there’s a well-developed working pipeline for medical devices in Wales, from the research frontiers through product development to the market. Prospective partners can enter this pipeline at any point – and from any country: the healthcare market is by definition global. Interdisciplinary and commercial collaborations cross international borders, and clinical trials are now being conducted throughout the world. That ability to move across boundaries –scientific, professional and geographical – is characteristic of the most active parts of the sector in Wales. The organisations outlined below demonstrate its impact on device innovations from the simplest to the most complex. This capability is one of the strongest factors that go to make the country such a promising base for international partnerships. The rapid growth of nanomedicine activities in Wales show native
organisations working at the highest international level. The Cardiff University Nanoscience Network (CuNN) connects research interests from basic sciences to regulation and ethics. It includes the Centre for Polymer Therapeutics, which put the world’s first polymer-based anticancer nanopharmaeutical into clinical trial in 1994. The Centre’s Director led the mapping out of nanomedicine’s future for the European Science Foundation’s 2005 Forward Look report, and was Course Director for the inaugural ESF Summer School in Nanomedicine at Cardiff in June of this year. At Swansea University, the NanoHealth partnership brings together the Multidisciplinary Nanotechnology Centre (MNC) and the recently-established Institute of Life Science (ILS). The MNC is a hub for the most advanced nanotechnology research throughout Wales and the site for cutting-edge facilities needed by its partners. The ILS is assembling a team of internationally acclaimed scientists across a range of related disciplines and its facilities include one of the largest IBM supercomputers in Europe, ‘Blue C’. The NanoHealth partnership’s four major areas of imaging, modelling, tissue repair and medical devices show the essential interactivity of different fields of expertise that is typical of highly complex innovations.
Swansea’s ILS is also home to the new Boots Centre for Innovation, which will be helping researchers and entrepreneurs from around the world to develop new products. A partnership deal between Alliance Boots plc and venture capitalists Longbow Capital LLP will offer the entrepreneurs access to investment funding. The Centre has outlined 10 key strategic areas for product research and development, which include pain relief, skin treatments, diabetes and healthy ageing. Boots has invested £3 million into the Centre, and believes that the prospect of distribution throughout Alliance Boots’ massive international network will draw in the most talented inventors to create new products for them. The management team is already attracting ideas from countries around the world including China, South Africa, America and Denmark. National and international collaboration is likewise a distinguishing feature of Zarlink Semiconductor, providing leadingedge semiconductor solutions for voice, enterprise, broadband and wireless communications. As part of the ‘Healthy Aims’ EU Framework VI project, which is developing a range of medical implants for the ageing and disabled population, Zarlink is focusing on novel in-body antenna design and ultra-low-power communications systems for implanted devices, such as hearing aids and muscle stimulators.
Meanwhile as a member of the European SHIFT project (Smart High-Integration Flex Technologies) Zarlink is working on flexible packaging technology for the personal medical device market, and its first SHIFT-enabled product demonstrator will be available at the end of 2007. The company is also leading a UKbased consortium of companies that is developing an in-body
microgenerator. The device will convert energy from human body movement into power for implanted medical devices, including pacemakers, electrical stimulators, instrumented joints and body area network applications. The project has received £500,000 in funding from the UK Department of Trade and Industry (DTI), which will be matchfunded by the consortium.
Medical Solutions
from
7
The award winning design consultants Established in 1987, GX is an independent design consultancy specialising in the original design and development of ground breaking products, advanced instruments and machines. GX has an extensive range of in-house services which include:
Industrial Design Mechanical Design Electronic Design Software Design Optronics Design Rapid Prototyping
GX Design Engineers The Mayfield Usk Monmouthshire NP15 1SY United Kingdom
For all enquiries contact Claire Banks
Tel +44 (0)1291 673437 Fax +44 (0)1291 673438 E-mail claire@gxl.co.uk Web www.gxl.co.uk
international pool of both speakers and delegates. Keynote speaker at Biowales 2008 will be Health Minister Lord Ara Darzi, whose interim review of the NHS has just been published.
Responsiveness to clinical need is an essential part of collaborative productivity, and the ability to translate needs into workable devices is equally visible in the development of simpler medical devices that have significant impact. Spin-out company ShakerScope provides the classic example of such a product. The ShakerScope is an eco-friendly, battery-free light source, which enables a range of essential medical instruments – including laryngoscope, otoscope and opthalmoscope – to be used in demanding environments and developing countries. Developed out of a clinical setting by consultant anaesthetists, the product has been supported throughout by Welsh organisational networks, receiving product design services and prototyping from PDR, grants from the Welsh Assembly Government’s Smart Cymru initiative, project management support from Welsh Innovations in Healthcare (WisH), and access to networks and collaborative opportunities through Mediwales. One of the most interesting models for bridging the clinical-commercial divide is that developed by Professor Gerfried Giebel in Germany and now being applied in Wales. The Giebel Round is a process of regular small meetings between equal numbers of clinicians and industrialists, held on active sites at clinical and company premises alternately. These reallife environments demonstrate the different needs and forces at work in
the clinical and commercial worlds, producing better – and speedier – solutions for the problems involved. Now funding from the EU ‘Innofire’ programme has enabled Wrexham County Borough Council to establish its own Giebel Round in North Wales. Already these meetings have resulted in four informal partnerships that are now working on new products. The Wrexham Giebel Round demonstrates how a Europe-wide example of best practice can be successfully applied at the local level, to bring through innovative marketable devices that meet important clinical needs. In terms of both national and international networking and collaboration, the annual BioWales conference has become a landmark in the Wales bioscience calendar, bringing together top names in the sector from an increasingly
At the heart of BioWales is the brokerage event organised by the Wales Innovation Relay Centre (WIRC), Welsh arm of the European-wide IRC network that fosters transnational technology transfer and innovative services. At each year’s BioWales brokerage, WIRC’s specialist expertise has consistently effected successful technology transfer agreements between academic institutions, multi-nationals and consortia. This brief scan indicates the highly active and diverse commercial profile, leading-edge research capability and well-developed support infrastructure that have enabled Welsh medical technology to consolidate its position in the international sector. With a strong focus on collaborating to innovate, and expertise in managing both the human and technological processes involved, Wales offers substantial opportunities for capitalising on these native assets to prospective partners both within and beyond its borders.
M e d i c a
S p e c i a l
2 0 0 7
WALES PAVILION DIRECTORY
10
11
International Business Wales
Jose Constantino Regional Manager - Europe,
Welsh Assembly Government Department for the Economy and Transport, Trafalgar House, 5 Fitzalan Place, Cardiff, Wales CF24 0ED United Kingdom Tel: +44 29 2082 8694 Fax: +44 2044 2696 Email: jose.constantino@wales.gsi.gov.uk Web: www.ibwales.com
BCB International International Business Wales (IBW) is the Welsh Assembly Government’s international trade and investment arm. It forms part of the Department for the Economy and Transport, and acts as the driving force in establishing alliances between companies in Wales and their counterparts overseas, whilst actively seeking out inward investment opportunities for client companies looking to Europe and the UK as a preferred international business location.
Biocatalysts Ltd, Unit 1, Cefn Coed Parc Nantgarw, Cardiff CF15 7QQ Tel: 01443 843712 Dax: 01443 846500 Mobile: 07974 922679 Email: theresac@biocats.com Web: www.biocatalysts.com
Biocatalysts Ltd is a specialist enzyme company based in the United Kingdom. It primarily manufactures enzymes for the Food and Diagnostic Kit markets but is different from the majority of enzyme companies in the world market because of its focus on custom-tailoring or developing “bespoke” enzyme systems for individual clients. Driven by its obsession with superior customer service Biocatalysts have gained an enviable reputation in the speciality enzyme market. The diagnostic enzyme range covers enzymes to test for a wide range of conditions and full details are available at www.biocatalysts.com
Biplas Medical Llantrisant Business Park, Llantrisant Rhonnda Cynon Taff, CF72 8LF Tel: 01443 237654 Fax: 01443 237433 Email: richard.bedwell@biplas.com Web: www.biplas.com
Innovative design and development company with manufacturing capability in plastic injection moulding. We develop devices using the latest technology in polymer and metallurgy with the required electronics using our associated partner. Offering know how and expertise based on our engineering and knowledge of a wide range of processes, capable of manufacturing the end product at a cost effective price. We are currently working on single use disposable devices in the field of laparoscopy, gynaecology and urology. We are working with leading clinicians in these areas to enabling the use of appropriate technology and processes to develop devices with patient need being the priority. Opportunities for partnerships are sort in the medical/healthcare arena enabling early stage devices and systems be developed, trialled and finally marketed via our distribution partners. We design and develop specialised packaging in the areas of radiology and bioscience.
Blizzard Protection Systems Limited Unit 2, Coed y Parc Industrial Estate Bethesda, Gwynedd LL57 4YY United Kingdom Tel: +44 (0)1248 600666 Fax:+44[0] 1248 600444 Web: www.blizzardsurvival.com Email: info@blizzardsurvival.com
Blizzard Protection Systems Limited based in Bethesda, North Wales develops, manufactures & markets a range of emergency survival products under the brand name Blizzard Survival. These products are used in the prevention & treatment of hypothermia in the evacuation of casualties in military, medical, emergency services and the outdoor sectors. Manufactured from Blizzard’s exclusive “Reflexcell” material the products represent a step change in the way both civilian & military trauma casualties can be treated. Ultra light, compact, portable and reusable, the products are unique, weight for weight warmer than goose down, yet 100% weatherproof. Blizzard kit is now recommended as the first choice for keeping casualties warm by the National Association of Emergency Medical Technicians and every medic in each of the United States Special Forces is being issued with the military version of the Blizzard Survival Blanket. Objectives at Medica To promote and develop the Blizzard Survival brand, engage potential customers and expand our presence in new markets
Lisa Owen Purchasing Manager
Biocatalysts TTems Ltd Rogerstone-South Wales Tregwilym Industrial Estate, Rogerstone, South Wales NP10 9YA Tel: +44 (0) 1633 892345 Fax:+44 (0) 1633 895755 Email:info@ttems.com Web: www.ttems.com
Abtest is an independent test house, part of the global electronic company, TT electronics plc. Certified UKAS, BS9000 and IECQ/CECC, Abtest works with customers in the automotive, telecommunications, medical, defence, aerospace and consumer markets. We specialise in climatic and dynamic environmental testing, functional and in-circuit test development, product investigative testing, electrical and mechanical calibration service. Equipped to handle a great range of standard tests, Abtest comes into its own when asked to custom-design new test regimes. The great range of technical skills of our staff and assets like our tool room are a major advantage. Abtest performs tests on products where quality, security, confidence and confidentiality are of the highest importance. Objectives at Medica: To increase market awareness and expand our customer base.
Stuart Ian West, Managing Director
Biplas Medical
Axiom Axiom Manufacturing Services Ltd Technology Park, Newbridge Newport NP11 5AN Tel: 01495 242130 Fax: 01495 242096 Email: garethb@axiom-ms.com Web: www.axiom-ms-com
Axiom Manufacturing Services focuses on providing contract electronic manufacturing services (EMS) to original equipment manufacturers (OEM’s) who do not want to manufacture some or all of their products in house. A complete range of electronics manufacturing services are available from design support, prototyping, new product introduction, PCB assembly, sub assembly, product assembly, test, warehousing and logistics through to after market services which includes repair and rework. Objectives at Medica Axiom are visiting Medica to network, look for new customers and learn more about the exhibition
Richard Bedwell Managing Director
Blizzard Survival
BBI Healthcare
Karl John Stanley Morris Sales Manager
BCB International Ltd has been a prime contractor to the life raft and lifeboat industry for over 50 years. We are a manufacturer and designer of survival equipment, primarily for the marine and military markets. Over 80% of BCB production is exported predominately to Europe, the Middle and Far East. BCB has a continuous and never ending innovation policy that has resulted in hundreds of quality innovative product over the years. Objectives at Medica: One of the many products we supply to our marine market is our solas approved medical first aid kits, as an ISO9001:2000 approved company we are always looking to form good working relationships with quality approved suppliers of medical products, our requirements are in the first instance to source new suppliers for existing medical products where current suppliers are failing us, however our other aim is to identify new exiting innovative products that fit within our product range and build new relationships with the designers/manufacturers to ensure we are always offering our customers the best and latest inventions that are available on the market to ensure safety of life in hostile environments.
Jose is in charge of the International Trade activities in the EU markets. He manages a network of business consultants based in key overseas markets and has overall responsibility for delivering IBW’s International Events programme in Europe.
AB Test
Gareth Beckett Senior Accounts Manager
BCB International Ltd Unit 7 Clydesmuir Road, Ind Est Tremorfa Cardiff CF24 2QS Tel: 029 20 433715 e-mail: la@bcbin.com Web: www.bcbin.com
BBI Healthcare Unit A Kestrel Way, Garngoch Ind Est Gorseinon, Swansea SA4 9WN Tel: 01792 229333 Fax: 01792 897311 Mobile: 0799 062889 Email: karlmorris@bbihealthcare.com Web: www.bbihealthcare.com
BBI Healthcare is a leading provider of diabetes care products to the global market place. As part of the successful BBI Holdings group (BBInternational, Biozyme, Seravac), the division was set up to source and develop diabetes solutions to complement the group’s range of diagnostic services. Since the south Wales based healthcare company was established in 2006, it already has a proven track record of commercializing diagnostic and healthcare products to the international market place. BBI Healthcare is currently looking for European distributors for its glucose tablets and leading GlucoGel brand, which has been widely available through the NHS since 1984. The company is also seeking new products which can be channeled through a number of territories including UK, Europe, North America and Australasia.
Howard Kendrick General Manager
M e d i c a
S p e c i a l
WALES PAVILION DIRECTORY
2 0 0 7
12
13
Enfis
Boots Centre for Innovation
Yvonne James / Louise Bryce
The Boots Centre for Innovation can provide support and funding for the Boots Centre for Innovation development of innovative products and technologies. We are particularly Institute of Life Science interested to meet people with new ideas and products to address the following Swansea University, Singleton Park consumer needs: Swansea SA2 8PP •Improve and maintain the health, look and feel of skin Tel: 01792 513722 Email: Yvonne.james@bootsinnovation.com •Improve the health and appearance of teeth and gums Web: www.bootsinnovation.com •Devices that enable people to monitor key aspects of their health •Improve the health, appearance and comfort of eyes •Improve digestive health issues, particularly related to stress, poor diet and obesity •Minimise the severity and duration of pain •Improve quality of sleep for everyone [including pregnant women, babies and the elderly •Minimise the complications of living with diabetes •Anti-ageing devices and products for mind and body •Create more convenient methods of using medicines and health products
David Pascoe
Cardiff Business Technology Centre provides flexible premises, business support and financial assistance, directly and via its partners, to help new start high technology companies grow successfully; and in concert with its sister centre, the Cardiff Medicentre - located on the University Hospital of Wales campus adjacant to the Cardiff Medical School (part of Cardiff University), looks to grow on companies into Cardiff and the City Region. With the proposed redevelopment of the Centre to provide a 100,000sq ft (10,000sq m) innovation centre closeby the main Cardiff University campus and the increasing internationalization of the commercial exploitation of new technologies, the company is looking at Medica to start to search out new contacts in international markets to meet this expanded and growing role.
Mark Stephen Coleman Senior Economic Development Officer
Cardiff Medicentre offers assistance in the development and commercial exploitation of innovative technology in the medical, life and bio-sciences. It is a joint venture of Cardiff University, Economic Development of Cardiff Council , the Cardiff and Vale NHS Trust and the Welsh Assembly Government; who each are able to provide support. Flexible accommodation, financial assistance and business support where needed offer an unrivalled package for early stage projects to reach successful fruition and to relocate into the city region. The centre is located on the main Medical School campus with units available from 280 sq ft upwards. Objectives at Medica To clarify the opportunities in international markets for the Cardiff offering.
Cellpath 80 Mochdre Enterprise Park Newtown, Powys SY16 4LE Tel: 01686 611333 Fax: 01686 622946 Email: Philip@cellpath.co.uk Web: www.cellpath.co.uk
Cellpath has established itself as a dynamic innovative company, and has an enviable reputation over 25 years for reliability and customer service in its role as market leading supplier of cellular pathology consumables. In addition to supplying a comprehensive range of pathology consumables, Cellpath continues to be at the fore-front of the design and development of new products. Cellpath has the resources to offer contract manufacturing, processing and packaging, as well as warehouse and distribution for customers looking to outsource these labour-intensive operations. Objectives at Medica Increase export market by meeting potential and existing suppliers, distributors and customers
The Mayfield Usk, Monmouthshire, Wales NP15 1SY United Kingdom Tel: +44 1291 673437 Fax: +44 1291 673438 Email: claire@gxl.co.uk Web: www.gxl.co.uk
GX Design Engineers offers a medical product design and development service from concept through to manufacture. This includes electronic, mechanical, optics, industrial and software design, prototyping and CAD animations. GX combines practical engineering solutions with creativity, innovation and focus within key services including industrial design, mechanical design, electronic hardware, design, software design, optical & optronic design and rapid prototyping. Medical projects have been undertaken for clients including Bayer Diagnostics, Gyrus Medical, Rhytec, CLP, Pall, Medical Support Systems, Morecare and British Gas. GX Design also provide FEA, Cosmos, Research for user, markets, materials and processes, branding, packaging and literature, model making and CAD animations. Objectives at Medica To introduce GX to the major medical manufacturing companies in Europe.
Haemair Ltd Unit 212 Digital Technium Swansea University Swansea SA2 8PP Tel: 01792 602466 Mobile: 07970 218709 Email: sbrown@haemair.com Web: www.haemair.com
The Haemair mission is to produce respiratory aids that range from devices that support respiration for patients with deficient lungs via an easily reversible fully external device to a prosthetic device that may replace human lungs. The basis of the device is a blood/air mass exchanger. This exchanger takes carbon dioxide from the blood and transfers oxygen into the blood. It is compact, portable and suitable for conscious, active patients. Unlike most conventional treatments for lung deficiency, the devices do NOT use the lungs, thus they allow deficient lungs to rest and recover. The product supports life by direct blood/air mass exchange. The novel features include incorporation of a control system that integrates with the body’s natural control mechanisms to respond to respiratory demand. Also, It employs natural air. Use of natural air has the benefit that the patient is not connected to an oxygen supply. Objectives at Medica To develop links with further companies in the medical device industry.
Crosswell Crymych, Pembrokeshire SA41 3UF Wales United Kingdom Tel: ++44 (0)1239 891656 Fax: ++44 (0)1239 891453 Email sales@holtain.co.uk Web: www.anthropometer.com
SO9001:2000 Accredited, Holtain Ltd manufacturer of the world famous “Harpenden” range of anthropometric instruments. The “Harpenden” instruments, which have been developed in close collaboration with the University of London Institute of Child Health, are counter recording and they give accurate and direct readings to the nearest millimetre. “Harpenden” instruments are so effortless in operation as to make possible a control of measurement unrealisable with conventional anthropometric instruments Should our range of items not meet the requirements of any project, please contact us and we will be more than happy to discuss modification or custom designed instrument.
GX Design Ltd
Claire Banks Sales Consultant
Haemair
Cardiff Medi Centre Cardiff Medi Centre Heath Park Cardiff CF14 4UJ Tel: 02920 87 3157 Fax: 02920 87 3233 Mobile: 07855 857 664 Email: mcoleman@cardiff.gov.uk
Enfis is a world-class provider and manufacturer of High Power LED light engines and arrays across a wide range of wavelengths; including white light, for use in medical and healthcare applications. With over 15 International patents, Enfis’s LED products can also be bought globally through distributors such as Digi-Key (www.digi-key.com) and Pacer (www.pacer.co.uk) Examples of medical applications that have already benefited from Enfis’s LED technology in preference to older traditional forms of lighting include: ● Neonatal treatment of Hyperbilirubinemia (jaundice in new born babies) ● Operating Room and Examination lighting ● Dental whitening and composite curing
Ali Yilmaz Sales Manager
Cardiff Business Technology Centre Cardiff Business Technology Centre Ltd Senghenydd Road Cardiff CF24 4AY Tel: 029 2087 2659 Fax: 02920 87 3233 Web: cbtc.co.uk Email: d.pascoe@cardiff.gov.uk
Enfis Ltd Technium 2 King’s Road, Swansea Waterfront Swansea SA1 8PJ
Steve Brown Senior Engineer
Cellpath
Philip Webber Managing Director Paul Webber Finance Director Brian Reid Export Sales Manager
Holtain
Niamh Holding Kenneth Dalziel
M e d i c a
S p e c i a l
WALES PAVILION DIRECTORY
2 0 0 7
14
15
Institute of Life Science
Karl Michael Hawkins Research Fellow
Medical Device Consultancy Institute of Life Science School of Medicine, Swansea University Singleton Park, Swansea SA2 8PP Tel: 01792 295202 Fax: 01792 295676 Mobile: 07711379116 Eamil: k.m.hawkins@swansea.ac.uk Web: http://www.medicine.swan.ac.uk/
The Institute of Life Science, is a purpose-built facility home to the School of Medicine’s research enterprise, housing internationally-recognised academics and scientists working at the boundaries of traditional disciplines. The institute creates an environment that draws on research expertise from the Schools of Science, Engineering and Business at Swansea University, enabling the School of Medicine to push forward the frontiers of knowledge with integrated support. Underpinning this innovative environment is a specialist business team, focused on building commercial-academic links in support of the Institute’s research and taking advances from the laboratory into hospitals, surgeries and homes. Opportunities will arise from areas such as research collaboration, intellectual property licensing, spinout companies and inward investment. Objectives at Medica To exploit research outcomes with internationally leading industries. To expand collaboration with leading international research centres.
JMJ Laboratories JMJ Laboratories, Gavenny Court, Brecon Road, Abergavenny, Monmouthshire NP7 7RX United Kingdom Tel: +44 (0) 1873 856688 Fax: +44 (0)1873 856688 Email: info@jmjlabs.co.uk Web: www.jmjlabs.co.uk
JMJ Laboratories Ltd provides pathology and workplace drug testing services to a wide variety of clients in the UK and overseas. Our fully accredited analytical services are supported by experts who can also provide advice and guidance for customers. In conjunction with our parent company – Synergy Healthcare - we can offer assistance with infection control programmes by providing fast results for MRSA using the latest technology. Our Toxicology department can help with implementing drug and alcohol policies, drug awareness and testing urine, hair or saliva samples for illegal drugs. JMJ also has a sample collection service which operates 24/7, enabling tests to be carried out at any time, anywhere.
Trevor Lewis Principal Consultant
Medical Device Consultancy 6 Bessborough Drive Cardiff, CF11 8NE Wales, UK Tel: +44 (0)29 2022 1640 Mobile +44 (0)7739 733177 Web: www.medicaldeviceconsultancy.co.uk Email: lewlink@btclick.com
Medical Device Consultancy provides specialist business reviews, planning and development consultancy to medical device, in vitro diagnostic (IVD) and related companies, including partner search and selection projects. Associates have particular strengths in medical device and in vitro diagnostic (IVD) regulatory compliance for Europe and North America, quality system establishment / improvement, auditing, process, product and software validation, marketing and product management. Medical Device Consultancy works with a specialist associates to provide in-depth assistance with: •Strategic business development and marketing advice. •Preparation for regulatory inspections or Notified Body quality system audits. •Regulatory documentation. •Can provide both European Authorised Representative and US Agent services. •Getting your medical device from concept to market – profitably. Objectives at Medica To meet possible new clients and associates.
Nightingale Care Beds Ltd Unit 20 Abenbury Way Wrexham Industrial Estate Wrexham LL13 9UZ Tel. +44 1978 661699 Fax +44 1978 661705 Email. kevineames@nightingalebeds.co.uk
Nightingale Care Beds produce specialist hospital beds and equipment to the NGS, private hospitals and other care facilities for the clinically obese (bariatric) and patients at risk of developing pressure ulcers. Pressure Area Care is provided throughout the ProAxis range of electric profiling of hospital beds by using of a Visco elastic mattress and the SMART Pressure Redistribution System. This is programmable movement of the mattress platform which provides dynamic redistribution of pressure. ProAxis Plus is a bariatric hospital bed, is supported by compatible, high quality batriatric equipment including patient hoists, rise/recline and static chairs, commodes, wheelchairs, walking frames and slings. Objectives at Medica Nightingale are actively looking for new innovative ideas to enhance their current range of patient care products. We are also looking to form strategic relationships with companies throughout Europe who share our ethos of quality, value and service.
PDR UWIC Western Avenue Cardiff CF5 2YB Tel: 02920 416725 Fax: 02920 416973 Email: ASpiteri-pdr@uwic.ac.uk Web: www.pdronline.co.uk
An established and world renowned centre for innovation, PDR undertakes world class design, engineering and product development support, from conceptual and premarket analysis, right through to detail and tool design to prototype, verification, batch manufacture and product launch. Combining the latest in research and knowledge with strong commercial discipline, experience and focus, PDR brings together the latest technologies and facilities with experienced, award-winning designers, engineers and technicians, to create unparalleled capability. Both the breadth and depth of experience and capability at PDR is impossible to find in a single location elsewhere in Europe. PDR has extensive experience in medical sector, and since its establishment over 13 years ago has helped many hundreds of companies, from major bluechips to start ups, to successfully innovate and grow. Objectives at Medica: •To strengthen and develop new client relationships •To gain a stronger presence in the medical industry •To promote PDR’s new service offerings •To promote new technologies and processes available in-house at PDR that will benefit product development and innovation in the medical sector
JMJ
Alison Payne Managing Director
Nightingale Care Beds Ltd
Kevin Eames Business Development Manager
Manufacturing Engineering Centre Manufacturing Engineering Centre Cardiff University, Queen’s Building Newport Rd, Cardiff, CF24 3AA Tel - 02920 87 4641 Mobile - 07940 077 197 Web: www.mec.cf.ac.uk Email: manufacturing@cf.ac.uk Geraint Evans Business Manager
MicroBridge is an open access service for industry and offers a comprehensive range of micro and nano structuring and machining capability for non-silicon materials. This includes micro and nano machining and micro fabrication and replication of structures from a few tens of nano metres to 1 mm. MicroBridge bridges the gap between conventional precision micro machining and the lithographic/direct write semiconductor patterning technologies for a wide range of different materials – from hard metals to softer polymers and for difficult-to-machine ceramics and glass. A range of process technologies are being offered, including picosecond laser ablation, micro electro-discharge machining, focussed ion-beam milling and nano imprinting and polymer replication processes. Nano and micro engineering offers a whole new range of product functionality that is not possible in larger scale. Sensors, medical and dental devices, health care and pharmaceuticals, automotive components, aerospace are a few sectors that are currently exploiting the opportunities offered by micro and nano engineering. Objectives at Medica To create awareness of what can be achieved from the MEC equipment and to increase the revenue from such leading edge technology.
PDR
Angela Spiteri Marketing Executive Julie Stephens Commercial Manager Jarred Evans Commercial Director
M e d i c a
S p e c i a l
2 0 0 7
WALES PAVILION DIRECTORY
17
16
Ruskinn Technology Ltd
Julia Foster Business Manager
Wound Healing Research Unit Ruskinn Technology Ltd Suite 3, Technium Centre Sony Technology Centre Pencoed, Bridgend CF35 5HZ Tel: 01656 868543 Fax: 01656 868541 Mobile: 07770 284577 Email: juliaf@ruskinn.com Web: www.ruskinn.com
Ruskinn Technology Ltd provides gas controlled incubation systems that constantly lead the way in innovation. The products are continuously refined to meet the changing and varied needs of the customer. The Ruskinn brand has existed since 1993 and became part of Biotrace in 2001. Ruskinn Technology Ltd was formed in February 2006 following a management buy out of the brand from Biotrace International. Objectives at Medica •To meet with existing distribution partners •To meet new / potential distribution partners •To understand investigate new products for our direct markets
TT electronic manufacturing services Ltd
Derek Bennett Business Development Manager
TT electronic manufacturing services Ltd (TTems) Tregwilym industrial estate Rogerstone, Newport NP10 9YA Tel: 01633 892345 Fax: 01633 895755 Email: info@ttems.com Web:www.ttems.com
Delivering electronic manufacturing solutions. As the largest UK-owned EMS providers, TT electronic manufacturing services Ltd (TTems) is an established manufacturer of electronic & electromechanical assemblies and finished products to the defence, telecommunications, automotive, medical and industrial sector. Its complete range of value added services covers design support and process optimisation, turnkey manufacturing and tailored logistics through to after sales support. In addition it provides life-cycle cost-efficiency combining UK-based NPI and low- to mid-volume production with a high volume low cost manufacture from its own facilities in China and Malaysia, both with UK programme-management. TTems demonstrates commitment to its customers through the implementation of lean and six-sigma technique and led to accreditation such as : ISO9001:2000, ISO14001, TS16949 and a Kitemark for quality standard IPC-A-610D.
Ultrawave Ltd Eastgate Business Park Wentloog Avenue Cardiff CF3 2EY Tel: +44 (0) 845 330 4236 Fax: +44 (0) 845 330 4231 E-mail: admin@ultrawave.co.uk Web: www.ultrawave.co.uk
Ultrawave have been manufacturing ultrasonic cleaners for over 15 years and are one of the largest independent UK manufacturers of precision ultrasonic cleaning equipment. Ultrawave’s extensive product range includes benchtop ultrasonic baths, industrial ultrasonic cleaners and custom-designed ultrasonic cleaning systems. At Medica 07, Ultrawave are exhibiting the Q-Series – a new range of benchtop ultrasonic cleaners which incorporate Frequency Leap technology to provide improved cleaning results. In addition, the Hygea™ 1250, Ultrawave’s HTM2030 compliant ultrasonic cleaner, designed specifically for surgical instrument cleaning, will be exhibi
Ultrawave
Centre for Complex Fluids Processing Centre for Complex Fluids Processing University of Wales Swansea, School of Engineering Singleton Park, Swansea, Wales, SA2 8PP United Kingdom Tel: +44 1792 295216 Fax: +44 1792 295676 Mobile: +44 7715419593 Email: g.m.coss@swansea.ac.uk Web: www.complexfluids.swan.ac.uk
The Centre for Complex Fluids Processing is a research centre in the School of Engineering at Swansea University. The Centre has been active in technology transfer since 1999 targeting environment, biotechnology, biomedical, food and engineering sectors. Complex fluids are a major feature of modern industry. Such fluids are extremely diverse in origin and composition, ranging, for example, from biotechnological materials and food products to mineral slurries and polymer melts. Underlying this diversity are certain properties that must be understood if the processing is to be effective and efficient. These include flow behaviour in process equipment, how the components of the fluid determine its overall properties and how individual components may be selectively separated. Such topics are the focus of the Centre for Complex Fluids Processing. Objectives at Medica To exploit research outcomes with internationally leading industries and expand collaboration with leading international research centres.
Dr Michael Clark Senior Research Fellow
Wound Healing Research Unit Upper Ground Floor, School of Medicine Cardiff University, Heath Park Cardiff CF14 4XN Tel: +44 (0) 29 2074 2323 Mob: + 44 (0) 7971 231195 Email: clarkm@whru.co.uk Web: www.whru.co.uk
The Wound Healing Research Unit (WHRU) at Cardiff University has an international reputation for investigating both acute and chronic human wounds particularly when these are non-healing or difficult wounds. The WHRU offers services in clinical care, research and education. Established in 1991 as the first research unit in the world to specialise in this subject, the WHRU aims to provide and continue to develop a world-class clinical, scientific and educational wound healing resource for the benefit of people with wound problems. It acts as an interface between healthcare providers, industry and the academic community to develop models of high quality care based on sound scientific research. The transfer of knowledge to clients is a key objective to ensure that new product development is in line with patient and clinical needs. Objectives at Medica •Maintain contact with current customers •Meet new commercial organisations where partnership with the WHRU may be mutually beneficial
M e d i c a
18
S p e c i a l
2 0 0 7
S H O W C A S E
BB International BB International is one of the companies leading the field in the development of point-of-care (POC) test diagnostics. Until recently, being tested for a condition to establish a diagnosis meant waiting for results to be processed by a central laboratory. But the new generation of POC diagnostic kits enable clinicians to confirm a diagnosis in minutes. POC testing enables high-prevalence conditions such as HIV and influenza to be controlled more effectively, and is increasingly used as an early screening device for patients that may be pre-disposed to certain conditions, so that they can receive preventative therapy before the illness takes hold. BBI, a South Wales-based provider of products and services for the global diagnostics market, is strategically positioned within the POC sector, estimated at $3 billion and identified as one of the fastest growing areas of the £23 billion ‘in-vitro’ diagnostics market. Manufacturers of laboratorybased tests are now looking to move into the POC industry, and BBI can help them to do so. The company was founded in 1986, and following an MBO in 1999, has built a blue-chip customer base of diagnostic companies. BBI supplies high quality reagents that customers use in the development of their own tests. The company’s ‘secret recipe’ gold colloid is the raw material that gives the ‘positive’ line as the visual indicator on a rapid test kit.
BBI also works with companies to develop such tests, and offers a full range of research, development manufacturing services from its Cardiff Headquarters, along with facilities in Dundee and Wisconsin, USA. The company has worked with partners on a number of test development projects, many of which have FDA approval, and estimates that BBI products have featured in around 4.5 billion diagnostic tests globally. BBI has worked on a number of projects where a company wishes to develop an existing Enzyme Linked Immunosorbent Assay (ELISA) to a less time-consuming and more versatile diagnostic platform. ELISAs are a common and usually laboratorybased form of diagnosis, and are often the only options for patient testing. The key and often most costly component of an ELISA is the protein used for detection. By turning their successful ELISA platform into a rapid test, ELISA manufacturers can maximize return on this valuable component. As a specialist in the field, BBI offers them a flexible solution in an efficient and
19
Haemair cost-effective development service, which includes a detailed feasibility study to ascertain the suitability of the protein for use in the development of a lateral flow assay. In a recent collaboration with a Netherlands organisation, BBI developed a rapid lateral flow assay for the detection of IgG antibodies to a peptide marker for Rheumatoid Arthritis (‘RA’). For this BBI used their POCkit® platform, an off-theshelf lateral flow platform that can reduce development time by up to six months. The assay provides an important and early diagnosis of RA, and will be used as a screening aid in conjunction with other laboratory and clinical findings.
Visitors to the British Science Museum saw a prototype of the world’s most ‘natural’ artificial lung over a six-week period this summer. The first device of its kind, the new artificial lung is unique in being able to adapt to the body’s changing needs, closely mimicking the behaviour of a human lung. The prototype on display in the Antenna science news gallery was developed by Swansea-based biomedical devices company Haemair Ltd, working with researchers at Swansea University with funding from EPSRC. The basis of the device is a blood/air mass exchanger that takes carbon dioxide from the blood and transfers oxygen into the blood. It is compact, portable and suitable for conscious, active patients. The device differs from current Extracorporeal Life Support (ECLS) systems in that is uses only natural air (rather than bottled or piped gases). It is also integrated with the natural respiratory control system so that transfer rates of oxygen and carbon dioxide respond naturally to physical activity. The use of specifically coated hollow fibre and/or flat sheet polymers within the mass exchanger avoids blood clots without the excessive use of anticoagulant drugs.
‘POCkit’: Opening the door on point-of-care technology
Unlike most conventional treatments for lung deficiency, the device does not use the lungs: it allows deficient lungs to rest and recover, rather than forcing damaged lungs to work harder through mechanically supported breathing. There is no comparable alternative device.
The Haemair mission is to produce a range of respiratory aids based on this device, from ones that support respiration for patients with deficient lungs - via an easily reversible fully external device - to a prosthetic device that may replace human lungs. The device is aimed at both acute and chronic lung conditions, offering hope to the one million people per year in Europe and North America alone who currently die of lung disease or damage. In the shorter term, the device has applications in the emergency treatment of patients with recoverable breathing failure such asthma, or trauma where lung function is severely impaired. It can be used in temporary but more enduring conditions, for example over a couple of weeks for treatment of patients with Acute Respiratory Infection (ARI), which currently kills 4 million people a year.
on the waiting list, and about 30% die during or soon after the operation. The device would enable transplant patients to be fitter and stronger for the operation, and better able to survive it. In the longer term, Haemair intend to develop a fully internal device offering an alternative to transplantation. Haemair welcomes enquiries regarding both commercial and academic collaborations, and is particularly interested in hearing from companies concerned with membranes and membrane surfaces, especially anti-thrombogenic surfaces, non-thrombogenic surfaces and biomimetic surfaces. Please contact Dr Steve Brown or Dr Bill Johns at the email addresses below. Haemair Ltd Unit 212 Digital Technium Swansea University Singleton Park Swansea SA2 8PP Tel: 01792 602466 Email: sbrown@haemair.com wrjohns@haemair.com Web: www.haemair.com
In the medium term, the device can act as a bridge for patients on lung transplant waiting lists who suffer from emphysema and cystic fibrosis. Currently, about 50% of patients die .
M e d i c a
20
S p e c i a l
2 0 0 7
S H O W C A S E
JMJ Laboratories The innovation of rapid molecular testing is enabling new ways to combat the spread of MRSA (methicillin-resistant Staphylococcus aureus) infections. JMJ Laboratories, a part of the Synergy Healthcare group, is using this technology to provide rapid screening for MRSA. Within the healthcare sector, screening for the presence of MRSA is becoming increasingly important as part of the drive to reduce incidences of the disease. MRSA kills approximately 5,000 people in the UK each year, and there were 3,500 episodes of MRSA reported between October 2005 and March 2006 alone. Between 5% and 7% of patients entering hospitals have been shown to be carrying MRSA, and if they are identified in advance they can be treated in isolation. JMJ Laboratories’ microbiology department is using a test developed by BD Diagnostics, the BD GeneOhm™ MRSA assay, which detects a gene sequence that is unique to the drug-resistant strain of the organism. The test is performed directly on a specimen taken from the patient’s nasal cavity. A commercially available instrument (PCRthermocycler) is used to amplify MRSA genetic material if present, and dedicated software interprets the data into a definitive assay result. The process provides definitive results within two hours of laboratory time in a single assay, as compared to the 24 to 72 hours necessary for analysing a
conventional microbiology-based culture. Results are returned electronically, and the timeline from sample receipt to delivery of results to the client is less than four hours. Because this rapid test leads to faster detection of MRSA colonisation in patients, it enables hospitals to implement swift, appropriate interventions which can prevent the transmission of infection, limit the costs associated with complications and treatment, and improve patient outcomes. BD Diagnostics have also recently obtained European CE Mark approval for their GeneOhmTM StaphSR assay, which will enable physicians to implement the right treatment earlier for patients with bloodstream infections. JMJ is pleased to be working with BD and can look forward to implementing their tests for detection of other serious infections including Clostridium difficile,
vancomycin-resistant Enterococci and Norovirus. JMJ Laboratories is a market leader in the field of clinical pathology and also in drugs abuse testing, holding UKAS accreditation for all appropriate tests and providing a nationwide service. Synergy Healthcare is one of the largest UK listed healthcare businesses with a long-established reputation in the field of infection prevention and control, and is a leading provider of outsourced healthcare support services within the UK, Europe and Asia.
Molecular Light Technology Research With new multi-million-pound, state-of-the-art manufacturing and R&D facilities in Cardiff, Molecular Light Technology Research is substantially expanding its portfolio of products and services. The company will begin production of innovative medical and industrial diagnostic test kits for Gen-Probe Inc. for its global markets, and will now for the first time be able to offer contract manufacturing services to cGMP standards for other companies and organisations. ‘We are working closely with partners to ensure that they gain maximum benefit from outsourcing their processes to Molecular Light Technology Research,’ explained International Operations Manager Damien Lucas. ‘We are able to accommodate a range of scenarios from companies at the process development and pilot scale stage, right through to those requiring higher volume processing and filling.’ The new facilities were opened by Professor the Baroness Finlay of Llandaff, President of the Royal Society of Medicine, in May this year. The expansion followed an investment of £2.9 million by parent company Gen-Probe Inc., and marked the start of plans to double turnover over the next five years. Molecular Light Technology Research was acquired by Gen-Probe Inc in 2003, as a platform both for further R&D technology development and to develop it into an international manufacturing centre.
Dr Ian Weeks, Director of Technology, shows the light emitted from the chemiluminescent reaction to Molly Price-Jones and Damien Lucas.
Established in 1991 as a spin-out from the University of Wales College of Medicine (now Cardiff University Medical School) Molecular Light Technology pioneered the development of highly sensitive diagnostic tests employing molecular technologies. Its chemiluminescent technology has been licensed externally, including in the USA, with FDA approval secured for chemiluminescence-based diagnostic tests. These tests are incorporated into products used worldwide, including 80% of all US blood bank testing for HIV and hepatitis C (HCV). Molecular Light Technology is already a Welsh biotech success story, with members of its R&D team responsible for 15 patents and over 80 published papers. ‘With the opening of the new facilities,’ said Managing Director Dr Molly Price-Jones, ‘the company is embarked on the next phase of its development as an international manufacturing centre of excellence in diagnostic test systems.’
Molecular Light Technology now aims to partner biotech innovators and suppliers in both this growing Welsh sector and across the rest of the UK. The development demonstrates the strength of diagnostics in Wales that attracts major international companies. Diagnostic product manufacture is a highly regulated and high-capital-cost activity and therefore one which many smaller companies find prohibitive. The expanded facilities enable Molecular Light Technology Research to provide up-and-coming Welsh companies with just the services to support that activity. Molecular Light Technology Ltd 5 Chiltern Close Cardiff Industrial park Llanishen Cardiff CF14 5DL Tel: Fax: Email: Web:
029 2074 7033 029 2074 7118 info@mltresearch.com www.mltresearch.com
23
M e d i c a
24
S p e c i a l
2 0 0 7
S H O W C A S E
The National Centre for Product Design and Development Research (PDR) Jarred Evans, Commercial Director of PDR commented, ‘With this award our talented team have bested competition from some of the world’s most innovative companies. I am delighted to showcase the exceptional expertise we have at PDR and in Wales at this international level’.
Leading-edge product design and development centre PDR has just become the first design company in Wales to receive an International Design Excellence Award (IDEA). The award was for its outstanding design work on a bariatric hospital bed, the ProAxis Plus, developed for Nightingale Beds.
PDR’s facilities and equipment are recognised as some of the best in the UK, and include Computer Aided Design (CAD) facilities; three rapid prototyping systems; 3D-scanning; CNC machining centres; injection moulding; low volume batch manufacturing facilities; and expert graphic design and marketing support services.
Most bariatric beds fail to consider patient and carer health risks. The ProAxis Plus has been cleverly engineered to maintain a functionality that is among the safest, most userfriendly and most practical on the market. Its ergonomically designed mattress and electronically controlled functions optimise patient comfort whilst alleviating the potential for manual handling injuries. Since its launch, the product has increased Nightingale’s sales figures by 286%. Nigel Quinn, Managing Director of Nightingale Beds commented, ‘Since The ProAxis Pressure Area Care System was introduced into the market, the response to date has exceeded all our expectations. The quality of PDR’s work throughout the project proved to be exceptional and their support through all phases was first class’. With over 1,600 entries from 30 countries, winning an IDEA is the ultimate compliment from the design industry and defines a design as the very best in business. Winners are selected by a panel of top
international designers and only pioneering products that have the ability to thrive in global markets are selected. Other notable winners this year include Apple and Kodak.
PDR has bagged a total of five prestigious international awards over the past two years – more than any other UK company. Part of the University of Wales Institute, Cardiff (UWIC), PDR is one of the UK’s leading centres for product design and development and is a Welsh Assembly Government-designated Centre of Excellence for Technology and Industrial Collaboration (CETIC).
With these in-house resources and capabilities PDR can take products from concept through to successful production and launch. Services include developmental research, product design and development, prototyping, low volume rapid manufacture, graphics, marketing and branding. For further information contact Angela Spiteri on 029 2041 6725. PDR The University of Wales Institute Cardiff Western Avenue Cardiff CF5 2YB Tel: 029 2041 6668 Fax: 029 2041 7080 Email: info-pdr@uwic.ac.uk Web: www.pdronline.co.uk
Wound Healing Research Unit The treatment of chronic wounds such as pressure ulcers and diabetic foot ulcers is big business. Recent estimates suggest that the National Health Service annually spends between £2.3 billion and £3.1 billion on their treatment – approximately 3% of the total expenditure on health – even before including the cost of surgical wounds, traumatic wounds and burns. The Wound Healing Research Unit (WHRU) at Cardiff University is one of the largest specialist wound healing centres worldwide. WHRU seeks to answer the fundamental questions:
●
Which interventions are truly effective?
●
How can we best intervene to optimise the wound environment to promote healing?
●
How should wound care be organised within the NHS to maximise clinical and economic outcomes?
●
How are health care professionals best prepared and educated to heal wounds effectively?
Established in 1991, the WHRU was the first research unit in the world to specialise in this subject. It has an international reputation for investigating both acute and chronic human wounds, particularly nonhealing or difficult wounds. Offering products and services in clinical care, research and education it aims to provide a world-class wound healing resource for the benefit of people with wound problems.
Accredited as a Centre of Excellence for Technology and Industrial Collaboration (CETIC) by the Welsh Assembly Government, the WHRU acts as an interface between healthcare providers, industry and the academic community to develop models of high-quality care based on sound scientific research. The transfer of knowledge to clients is a key objective to ensure that new product development is in line with patient and clinical needs. WHRU has been working in partnership with manufacturers both local to Wales and throughout the UK as well as with global organisations, to explore prototypes in the laboratory, identify potential clinical benefits and follow through to leadership of multinational clinical trials. In autumn 2007 the WHRU successfully bid for funds to help establish a Welsh Wounds Special Interest Group, as a focus for
collaboration between academics, clinicians and the biotechnology commercial sector. The Welsh Wounds Special Interest Group offers real potential for closer collaboration and new partnerships, and will showcase the value of working in Wales for organisations and individuals with interest in wounds and wound healing. If you would like further information on the work of the Wound Healing Research Unit and the Welsh Wounds Special Interest Group, please phone or email us at the address below.
Wound Healing Research Unit (WHRU) School of Medicine Cardiff University Heath Park Cardiff CF14 4XN Tel: 029 2074 4505 Fax: 029 2075 6334 Email: admin@whru.co.uk Web: www.whru.co.uk
25
Wireless Technology for Medical Systems M e d i c a
2 0 0 7
S H O W C A S E “Medical companies should have a quicker, easier and lower cost way of getting wireless technology to market”
Zarlink Semiconductor
Zarlink’s Microelectronics division delivers, with:
Zarlink Semiconductor has joined the European SHIFT Project (Smart High-Integration Flex Technologies) to develop flexible, highly integrated packages for emerging electronicconsumer systems, including medical devices, portable communication tools, smart cards and aerospace utomotiveapplications. Co-funded by the European Commission, the SHIFT Project consortium consists of R&D institutes, industrial flex manufacturers, end-users and a technology support agency. Zarlink’s participation in the SHIFT Project is based in its Caldicot, UK site. The company’s work will be initially focused on developing flexible packaging technology for the personal medical device market. The first SHIFT-enabled product demonstrator from Zarlink will be available at the end of 2007.XX year. With the increase in electronics systems that are located near, on or even implanted in patients, product manufacturers are seeking lightweight, flexible and compact designs to increase product functionality, user comfort and convenience. The embedding of components in flexible materials such as polyimides will be used as the basis of these products. To boost the combination of high functionality and compactness as well as user comfort, there is a need for substantial development in the use of embedded components in flex substrates.
• Proven micro-packing expertise supporting smaller, faster and more reliable technologies • End-to-end design knowledge ensuring faster time-to-market • Manufacturing capabilities meeting worldwide medical standards
6ZS385
26
S p e c i a l
The future is flexible at Zarlink Advanced Packaging Business. ‘Medical electronic systems that move along with the user increasingly require more functionality, and must be extremely small, lightweight and available at a reasonable price,’ said David Heatherall, external project leader at Zarlink’s Caldicot facility. ‘This trend is just starting and it’s clear that we need to advance ‘smart’ packaging technology, which means developing a flexible multilayer structure supporting multiple functions.’ Zarlink’s Caldicot facility is a leader in advanced micropackaging solutions for medical, high reliability and security markets. It offers unique SIP (system-in-package)solutions that give customers the flexibility to incorporate a higher components count and greater functionality in a smaller space than that typically found in conventional electronic assemblies. Zarlink’s micro-packing expertise is at the heart of missioncritical and cutting-edge medical device applications.
Zarlink’s combined ultra-low power and RF (radio frequency) design know-how is enabling a wide range of advanced healthcare products, including the world’s first swallowable camera capsule and wirelessly enabled implanted medical devices supporting new monitoring, diagnostic and therapeutic applications.
Zarlink Semiconductor Castlegate Business Park Portskewett, Caldicot NP26 5YW Tel: 01291 435300 Fax: 01291435291 Email: Ed Goffin, Media Relations edward.goffin@zarlink.com Martin McHugh, Business Development martin.mchugh@zarlink.com Ian James, Business Development ian.james@zarlink.com Web: www.zarlink.com Web for SHIFT project: www.shift-project.org
http://micro.zarlink.com
Zarlink Semiconductor—Microelectronics Phase 2, Castlegate Business Park Portskewett, Caldicot, Monmouthshire NP26 5YW Tel: +44 (0) 1291 435300